PLoS Pathogens (Oct 2022)

An introduction to the Marburg virus vaccine consortium, MARVAC

  • Robert W. Cross,
  • Ira M. Longini,
  • Stephan Becker,
  • Karin Bok,
  • David Boucher,
  • Miles W. Carroll,
  • Janet V. Díaz,
  • William E. Dowling,
  • Ruxandra Draghia-Akli,
  • James T. Duworko,
  • John M. Dye,
  • Michael A. Egan,
  • Patricia Fast,
  • Amy Finan,
  • Courtney Finch,
  • Thomas R. Fleming,
  • Joan Fusco,
  • Thomas W. Geisbert,
  • Anthony Griffiths,
  • Stephan Günther,
  • Lisa E. Hensley,
  • Anna Honko,
  • Ruth Hunegnaw,
  • Jocelyn Jakubik,
  • Julie Ledgerwood,
  • Kerstin Luhn,
  • Demetrius Matassov,
  • Jeffrey Meshulam,
  • Emily V. Nelson,
  • Christopher L. Parks,
  • Roxana Rustomjee,
  • David Safronetz,
  • Lauren M. Schwartz,
  • Dean Smith,
  • Paul Smock,
  • Ydrissa Sow,
  • Christina F. Spiropoulou,
  • Nancy J. Sullivan,
  • Kelly L. Warfield,
  • Daniel Wolfe,
  • Courtney Woolsey,
  • Roland Zahn,
  • Ana María Henao-Restrepo,
  • César Muñoz-Fontela,
  • Andrea Marzi

Journal volume & issue
Vol. 18, no. 10

Abstract

Read online

The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine “MARVAC” consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectious disease threat. Here, we discuss current progress, challenges, and future directions for MARV vaccines.